Germany is the first European country to launch the product, with further rollouts across Europe to follow
The next-generation oral fumarate therapy is designed to improve gastrointestinal tolerability and support long-term adherence
Barcelona, Spain and Düsseldorf, Germany – 2 October, 2025 – Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, today announces the launch of Riulvy® (tegomil fumarate) in Germany, the product’s first introduction into the European market.
Tegomil fumarate is a next-generation oral fumarate therapy developed for the treatment of relapsing-remitting multiple sclerosis (RRMS) in adults and adolescents from 13 years of age1. Designed as a ‘next-generation oral fumarate’, Riulvy® provides equivalent efficacy to existing fumarate therapies while offering a favorable gastrointestinal tolerability profile. 2,3
Around 2.8 million people live with MS worldwide with an average prevalence of 36 per 100,000 people. In Europe the average prevalence is even higher (133 per 100,000), with 300 per 100,000 in Germany.4
The launch marks another important milestone in Neuraxpharm’s ongoing commitment to enhancing treatment options in multiple sclerosis (MS), ensuring patients and physicians have new solutions to support long-term management of the disease.
Dr. Jörg-Thomas Dierks, Chief Executive Officer of Neuraxpharm, said: “This launch in Germany represents another significant achievement in our mission to bring innovative therapies to people living with CNS disorders. We now add a new oral fumarate therapy to our expanding multiple sclerosis portfolio which offers patients and neurologists more flexible, differentiated options in MS management.”
Tegomil fumarate, a co-development in collaboration with Tiefenbacher Group, received European Commission marketing authorisation in July 2025, with Germany as the first country to launch in October 2025. Additional launches across Europe are planned.